Cardiac hormones inhibit proliferation of pancreatic cancer but not normal cells

European Journal of Clinical Investigation

Volumn 40, Issue 8, 2010, Pages 706-712

  Skelton IV, William P ^a,c   Pi, Guillermo ^a,b   Lenz, Anne ^c   Sun, Ying ^c   Vesely, David L ^c  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cancer; cardiac hormones; proliferation; therapeutics; toxicity

Indexed keywords

ATRIAL NATRIURETIC FACTOR; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; UNCLASSIFIED DRUG; VESSEL DILATOR PEPTIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; DRUG EFFECT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ATRIAL NATRIURETIC FACTOR; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; HUMANS; KIDNEY; LUNG; MALE; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PROSTATE; PROTEIN PRECURSORS;

EID: 77954527379     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02309.x     Document Type: Article

References (22)

1. Vesely DL Natriuretic hormones. In : Alpern RJ, Herbert SC, editors. The Kidney: Physiology and Pathophysiology, 4th edn.
2. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL et al. Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 2007 21 : 445 452. (Pubitemid 46901402)
3. Vesely BA, McAfee Q, Gower WR Jr., Vesely DL. Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 2003 33 : 998 1005.
4. Gower WR Jr., Risch RM, Godellas CV, Fabri PJ. HPAC, a hew human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In Vitro Cell Dev Biol 1994 30A : 151 161.
5. Cory AH, Owen TC, Barltop JA, Cory JG. Use of an AQueous soluble tetrazolium/formazan assay for growth assays in culture. Cancer Commun 1991 3 : 207 212.
6. Abell TJ, Richards AM, Ikram H, Espiner EA, Yandle T. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet derived growth factor. Biochem Biophys Res Commun 1989 160 : 1392 1396.
7. Yu SM, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibition of the activation of epidermal growth factor signaling pathway. Circulation 1997 95 : 1269 1277.
8. Pedram A, Razandi M, Hu RM, Levin ER. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 1997 272 : 17097 17103.
9. Johnson A, Lermioglu F, Garg UC, Morgan-Boyd R, Hassid A. A novel biological effect of atrial natriuretic hormone: inhibition of mesangial cell mitogenesis. Biochem Biophys Res Commun 1988 152 : 893 897.
10. Itoh H, Pratt TE, Ohno M, Dzau VJ. Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. Hypertension 1992 19 : 758 761.
11. Haneda M, Kikkawa R, Koya D, Sakamoto K, Nakanishi S, Matsuda Y et al. Biological receptors mediate anti-proliferative action of atrial natriuretic peptide in cultured mesangial cells. Biochem Biophys Res Commun 1993 192 : 642 648. (Pubitemid 23227371)
12. Volmar AM, Schmidt KN, Schultz R. Natriuretic peptide receptors on rat thymocytes: inhibition of proliferation by atrial natriuretic peptide. Endocrinology 1996 137 : 1706 1713.
13. Appel RG. Mechanism of atrial natriuretic factor-induced inhibition of rat mesangial cell mitogenesis. Am J Physiol 1990 25 : E312 8.
14. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 2006 26 : 3217 3222. (Pubitemid 44701488)
15. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res 2006 26 : 4143 4148. (Pubitemid 46031483)
16. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007 27 : 1387 1392.
17. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007 27 : 3813 3818.
18. Sun Y, Eichelbaum EJ, Lenz A, Skelton WP IV., Wang H, Vesely DL. Atrial natriuretic peptide and long-acting natriuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 2009 29 : 1889 1893.
19. Sun Y, Eichelbaum EJ, Skelton WP IV., Lenz A, Regales N, Wang H et al. Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 2009 29 : 971 975.
20. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F et al. Roles in the Raf/MEK/ERK pathway in cell growth, malignant transformation, and drug resistance. Biochim Biophys Acta 2007 1773 : 1263 1284.
21. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004 4 : 937 947.
22. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide activate ERK 1/2 kinases in fibroblasts. Horm Metab Res 2009 41 : 197 201.